Posted by Michael Wonder on 15 Dec 2021
U.S. FDA grants priority review for spesolimab for the treatment of flares in patients with generalised pustular psoriasis, a rare, life-threatening skin disease
15 December 2021 - Additionally, FDA granted breakthrough therapy designation for spesolimab in the treatment of generalised pustular psoriasis flares.
Boehringer Ingelheim today announced that the U.S. FDA has accepted a biologics license application and granted priority review for spesolimab for the treatment of generalised pustular psoriasis flares.
Spesolimab is a novel, humanised, selective antibody that blocks the activation of the interleukin 36 receptor, a signalling pathway within the immune system shown to be involved in the pathogeneses of several autoimmune diseases, including generalised pustular psoriasis.
